Aditxt, Inc., a biotech company incorporated in Delaware, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on September 6, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This move allows Aditxt to potentially sell up to $150,000,000 of common stock to Seven Knots, LLC from time to time after the effective date of the registration statement. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'ADTX.' The registration statement includes a preliminary prospectus detailing the potential resale of shares by Seven Knots to the public. The purchase price for the shares will be based on formulas set forth in the Purchase Agreement depending on the type of...Show More

Aditxt, Inc., a biotech company incorporated in Delaware, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on September 6, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This move allows Aditxt to potentially sell up to $150,000,000 of common stock to Seven Knots, LLC from time to time after the effective date of the registration statement. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'ADTX.' The registration statement includes a preliminary prospectus detailing the potential resale of shares by Seven Knots to the public. The purchase price for the shares will be based on formulas set forth in the Purchase Agreement depending on the type of purchase notice submitted to Seven Knots. Aditxt will cover the expenses incurred in connection with the issuance of shares. As of the date of the prospectus, no shares have been issued or sold under the Purchase Agreement. The company's leadership team, led by CEO Amro Albanna, believes this strategic move will provide financial flexibility and support for future growth initiatives.